companies / trimtech-bio
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-08 json
| total_raised | 31,000,00031.0M | ○ |
|---|---|---|
| founded | 2024 | |
| hq | Cambridge, UK | |
| industry | unknown | |
| stage | seed |
Trimtech Therapeutics develops targeted protein degraders, branded TRIMTACs and TRIMGLUEs, that selectively remove disease-causing proteins to treat CNS and inflammatory disorders. It is built for patients with intractable disease driven by toxic protein buildup. Its programs use TRIM21, a widely expressed but underused ubiquitin ligase.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-03-15 | seed | 31,000,00031.0M | null | ○ |
| fact | status | src |
|---|---|---|
| Seed, $31.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |